*Content only available in French.
AbortionInCanada. (n.d.) Funding. http://abortionincanada.ca/funding/
ACMTS. (2016). Appel de rétroaction des patients : Mifegymiso. https://www.cadth.ca/fr/nouvelles/appel-de-retroaction-des-patients-mifegymiso
Beauchamp, T. L. (2006). The ‘Four Principles’ Approach to Health Care Ethics, in Principles of Health Care Ethics, Second Edition. John Wiley & Sons: Chichester, UK. DOI 10.1002/9780470510544.ch. 1
Bannert, M. and Iselin, D. (2015). Ask Your Doctor or Pharmacist! On the Effect of Self-Dispensing Physicians on Pharmaceutical Coverage. (KOF Working paper No. 15-387). KOF Swiss Economic Institute, ETH Zurich: Zurich. DOI 10.3929/ethz-a-010479991
Canadian Abortion Providers Support (CAPS). (2017). Frequently Asked Questions : General Information-Mifegymiso. https://www.caps-cpca.ubc.ca/skins/FAQcaps.pdf
Chan, C. (2016). A Canadian Perspective on Mifepristone (RU-486) and Abortion Services. Journal of Contraceptive Studies, 1(1-5), 1-2. http://contraceptivestudies.imedpub.com/a-canadian-perspective-on-mifepristone-ru486-and-abortion-services.pdf
Costescu, D., Guilbert, E., Bernardin, J., Black, A., Dunn, S., Fitzsimmons, B., Norman, W.V., Pymar, H., Soon, J., Trouton, K., Wagner, M.S., Wiebe, E., Gold, K., Murray, M.E., Winikoff, B. and Reeves, M. (2016). Medical Abortion. Journal of Obstetrics and Gynaecology Canada, 38(4), 366-389. DOI 10.1016/j.jogc.2016.01.002
Dressler, J., Maughn, N., Soon, J.A. and Norman, W. V. (2013). The Perspective of Rural Physicians Providing Abortion in Canada: Qualitative Findings of the BC Abortion Providers Survey (BCAPS). PLOS ONE, 8(6), e67070. DOI 10.1371/journal.pone.0067070
Dunn, S. and Cook, R. (2014). Medical abortion in Canada: behind the times. Canadian Medical Association Journal, 186(1), 13-14. DOI 10.1503/cmaj.131320
Fédération du Québec pour le planning des naissances (FQPN). (2017). Avortement. http://www.fqpn.qc.ca/public/informez-vous/grossesse-non-planifiee/avortement/
Gomez, A. M., Fuentes, L., and Allina, A. (2014). Women or LARC First? Reproductive Autonomy and the Promotion of Long-Acting Reversible Contraceptive Methods. Perspectives on Sexual and Reproductive Health, 46(3), 171–175. DOI 10.1363/46e1614
Institut National d’Excellence en Santé et Services Sociaux (INESSS). (2017). L’interruption volontaire de grossesse pratiqué à l’aide du Mifegymiso: efficacité, innocuité, organisation des soins et considérations économiques. Quebec: INESSS, 1-54. https://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS-IVG-Mifegymiso.pdf
Mifeprex REMS Study Group. (2017). Sixteen Years of Overregulation: Time to Unburden Mifeprex. New England Journal of Medicine, 376, 790-794. DOI 10.1056/NEJMsb1612526
Norman, W.V. (2012). Induced abortion in Canada 1974–2005: trends over the first generation with legal access. Contraception, 85(2), 185-191. DOI 10.1016/j.contraception.2011.06.009.
Norman, W. V., and Soon, J. A. (2016). Requiring physicians to dispense mifepristone: an unnecessary limit on safety and access to medical abortion (Report). Canadian Medical Association Journal, 188(17-18), 429-430. DOI 10.1503/cmaj.160581
Santé Canada. (2016a). Médicaments et produits de santé : MIFEGYMISO. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2016-mifegymiso-160063-fra.php#smd
Santé Canada. (2016b). Sommaire de décision règlementaire : MIFEGYMISO. http://hc-sc.gc.ca/dhp-mps/prodpharma/rds-sdr/drug-med/rds_sdr_mifegymiso_160063-fra.php
Santé Canada. (2016c). Médicaments et produits de santé : Mifegymiso- Mythes ou réalités. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/fs-fi/mifegymiso-fs-fi-fra.php
Vogel, K.I., LaRoche, K.J., El-Haddad, J., Chaumont, A. and Foster, A.M. (2016). Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients. Contraception, 94(2), p.137-142. DOI 10.1016/j.contraception.2016.04.008.
Comments